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A single asymmetric division by an adult neural stem cell (NSC) ultimately generates
dozens of differentiated progeny, a feat made possible by the proliferative expansion of
transit-amplifying progenitor cells (TAPs). Although NSC activation and TAP expansion is
determined by pro- and anti-proliferative signals found within the niche, remarkably little is
known about how these cells integrate simultaneous conflicting signals. We investigated
this question focusing on the subventricular zone (SVZ) niche of the adult murine
forebrain. Using primary cultures of SVZ cells, we demonstrate that Epidermal Growth
Factor (EGF) and Bone Morphogenetic Protein (BMP)-2 are particularly powerful pro- and
anti-proliferative factors for SVZ-derived neural precursors. Dose-response experiments
showed that when simultaneously exposed to both signals, BMP dominantly suppressed
EGF-induced proliferation; moreover, this dominance extended to all parameters of
neural precursor behavior tested, including inhibition of proliferation, modulation of cell
cycle, promotion of differentiation, and increase of cell death. BMP’s anti-proliferative
effect did not involve inhibition of mTORC1 or ERK signaling, key mediators of
EGF-induced proliferation, and had distinct stage-specific consequences, promoting
TAP differentiation but NSC quiescence. In line with these in vitro data, in vivo experiments
showed that exogenous BMP limits EGF-induced proliferation of TAPs while inhibition of
BMP-SMAD signaling promotes activation of quiescent NSCs. These findings clarify the
stage-specific effects of BMPs on SVZ neural precursors, and support a hierarchical
model in which the anti-proliferative effects of BMP dominate over EGF proliferation
signaling to constitutively drive TAP differentiation and NSC quiescence.
Keywords: adult neurogenesis, subventricular zone, BMP, EGF, neural precursors, mTOR, quiescence,
proliferation
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INTRODUCTION
Neural stem cells (NSCs) are essential for the normal function,
maintenance, and injury-induced repair of the adult central
nervous system (CNS). Although only a small percentage of NSCs
is cycling at any given moment, they are able to accomplish these
critical functions by producing and maintaining a large pool
of transit-amplifying progenitor cells (TAPs). In the forebrain
subventricular zone (SVZ) niche, lineage analysis suggests that
each TAP undergoes about 3–4 rounds of rapid proliferative
expansion before differentiating, allowing a single asymmetric
division by an activated NSC to ultimately give rise to as many
as 32 neuroblasts (Ponti et al., 2013). TAP-derived neuroblasts
and glial cells are required to maintain specific subpopulations of
forebrain neural cells (Menn et al., 2006; Imayoshi et al., 2008;
Luo et al., 2008) and to contribute to tissue repair following brain
injury (Yamashita et al., 2006; Kolb et al., 2007; Benner et al.,
2013). Since SVZ NSCs are typically quiescent, re-entering the
cell cycle only once every 2–3 weeks (Morshead et al., 1994),
NSC roles in CNS homeostasis and repair are critically dependent
on both NSC activation and, importantly, the proliferative
expansion of their downstream TAPs.
Proliferation of NSCs and TAPs (herein, collectively referred
to as neural precursors) is promoted by many families of
molecules within the SVZ niche (Gage, 2000; Alvarez-Buylla and
Lim, 2004; Pathania et al., 2010; Bond et al., 2012), including the
Epidermal Growth Factor (EGF) family. EGF family members
signal through the Epidermal Growth Factor Receptor (EGFR),
a cell surface tyrosine kinase receptor expressed in activated
NSCs (Doetsch et al., 2002; Pastrana et al., 2009; Codega
et al., 2014) and in the highly proliferative TAPs (Sun et al.,
2005; Ferron et al., 2011). Ligand-induced activation of EGFR
stimulates proliferation of activated NSCs and TAPs in vivo
and allows neural precursor expansion as neurospheres in vitro
(Reynolds and Weiss, 1992; Craig et al., 1996; Paliouras et al.,
2012). Conversely, mice deficient for EGFR ligands show reduced
SVZ neurogenesis (Tropepe et al., 1997). Multiple downstream
signaling cascades are initiated upon EGFR activation, including
the Akt-mTOR pathway. EGF treatment of cultured neural
precursors stimulates mTOR activation within minutes, and
EGF-induced mTOR activation is essential for proliferative
expansion of the NSC lineage both in vitro and in vivo (Feliciano
et al., 2011; Magri et al., 2011; Paliouras et al., 2012; Hartman
et al., 2013).
The signaling mechanisms that counterbalance EGFR-
induced proliferation in order to promote neural precursor
quiescence are considerably less understood. Indeed, while
many niche-derived factors modulate cell proliferation and/or
neurogenesis within the SVZ (Pathania et al., 2010), how
the ensemble of these signals is integrated within specific
cell populations to coordinate the quiescence/proliferation/
differentiation decisions of neural precursors is unclear. Here,
we focused on bone morphogenetic proteins (BMPs). BMPs are
expressed locally within the SVZ, where they have been shown to
promote production of astrocytes at the expense of neurons and
oligodendrocytes (Lim et al., 2000; Morell et al., 2014). Inhibition
of endogenous BMP signaling modulates neurogenesis in both
the SVZ and dentate gyrus niches, although there is conflicting
data that likely reflects unresolved stage-specific effects on the
neurogenic lineage and differences between niches (Lim et al.,
2000; Bonaguidi et al., 2008; Colak et al., 2008; Gobeske et al.,
2009; Mira et al., 2010; Guo et al., 2011; Bond et al., 2012, 2014).
In the present study, we ask how SVZ NSCs and TAPs
integrate opposing pro- and anti-proliferation signals. Our
findings reveal a hierarchical relationship between two key niche
signals, EGFR ligands and BMPs, in regulating the quiescence/
proliferation/differentiation decisions of SVZ neural precursors.
MATERIALS AND METHODS
Animals
C57BL/6 mice at 2–3 months of age were used for this study
(Charles River). Experiments were conducted in accordance
with the guidelines of the Canadian Council of Animal Care
and were approved by the institutional ethics review committees
of the University of Montreal and the Research Center of the
University of Montreal Hospital (CRCHUM). In vivo procedures
were performed with mice under isoflurane general anesthesia
supplemented with injection of Buprivacaine local anesthetic
(Hospira) (1mg/kg). Mice were euthanized by injection
of a mixture of ketamine (Bimeda-MTC)/xylazine (Bayer
Healthcare)/acepromazine (Boehringer Ingelheim Canada Ltd)
(200/10/2mg/kg).
Cell Culture Experiments
Clonally-derived neurosphere cultures were generated from the
adult mouse striatum using a protocol based on Reynolds
and Weiss (Reynolds and Weiss, 1992) and as detailed
previously (Bouab et al., 2011; Paliouras et al., 2012). Standard
neurosphere growth medium consisted of DMEM:F12 (3:1,
Invitrogen), Penicillin/Streptomycin (1%, Wisent), Fungizone
(1mg/ml, Invitrogen), and B27 (2%, Invitrogen), supplemented
with 20 ng/ml EGF (Sigma). In some experiments, we used
additional extrinsic factors that included FGF-2 (Feldan), BMP-
2 (Peprotech), PDGF-AA (Peprotech), VEGF-C (Peprotech), or
SHH (Peprotech), as indicated. Cultures of primary neurospheres
were passaged by mechanical dissociation and were expanded at
a clonal plating density of 2000 cells/cm2. Primary neurospheres
were used in quantitative neurosphere assays (i.e., counts of
clonally-derived neurospheres). Secondary neurospheres were
used when it was necessary to amplify neural precursor numbers
for high-density adherent cultures for biochemical and flow
cytometry analyses.
For the pro-proliferative assay, neurospheres were
mechanically dissociated and plated at a high density of 25,000
cells/cm2 in a basal differentiation medium [i.e., neurosphere
growth medium in which EGF was replaced with 2% Fetal
Bovine Serum (FBS, Wisent)] and treated with 20 ng/ml of each
extrinsic factor.
For the anti-proliferative assay, SVZ-derived cells were plated
in non-adherent 24-well plates in medium containing a basal
EGF concentration of 5 ng/ml (EGFlow) to sustain neurosphere
formation and treated on day 0 with 100 ng/ml of each extrinsic
factor.
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For the dose-response experiments, neurospheres were
dissociated and plated on coated dishes at a density of 25,000
cells/cm2 for 6 days in medium containing 2% FBS to promote
cell adherence and survival. Cells were treated on days 0 and 3
with the indicated concentrations of EGF and/or BMP-2.
For Olig2 labeling and Ki67-TUNEL double-labeling,
neurospheres were dissociated and plated on coated dishes at
a density of 25,000 cells/cm2 for 2 days in medium containing
5 ng/ml EGF (EGFlow) and 1% FBS. Adherent cells were treated
on day 0 with 100 ng/ml of EGF and/or BMP-2, and were
processed after 2–3 days for immunofluorescence labeling.
For the experiments comparing the effects of transient
treatment with BMP-2 and Rapamycin treatment, neurospheres
were dissociated and plated at 25,000 cells/cm2 in medium
containing 5 ng/ml EGF (EGFlow) and 1% FBS, supplemented
with either 100 ng/ml BMP-2 or 20 nM Rapamycin (Tocris).
After 24 h of treatment (1DIV), cells were washed twice with
DMEM/F12 and then placed in medium containing 20 ng/ml
EGF supplemented with 1% FBS for adherence/survival for an
additional 4 days. Cells were lysed daily up to 5DIV (i.e., up to 4
days after withdrawal of BMP-2 or Rapamycin).
For self-renewal assays, growth factor treatments were
performed during primary neurosphere growth, then 60 average-
sized primary neurospheres/condition were collected manually,
mechanically dissociated, and the cells counted and re-seeded
at clonal density (1.5 cells/µl) in standard neurosphere growth
medium (above); this allowed quantification of the number of
secondary neurospheres generated and retrospective calculation
of the mean number of neurosphere-forming NSCs that were
present per primary neurosphere.
Neurosphere numbers were quantified by plating cells in 24-
well plates at the clonal densities indicated above (minimum
of 8 wells/treatment/N). Neurosphere sizes were quantified by
measuring the diameter of at least 100 neurospheres/condition
using ImageJ software (version 1.47 v, NIH, USA), and the data
expressed using frequency histograms [GraphPad Prism, Version
5.02 (GraphPad Software, Inc)].
In vivo Experiments
Intracerebroventricular (ICV) infusions were performed using
7 days osmotic pumps (Alzet, model 1007D, Durect) that were
attached to brain infusion cannulae (Alzet, Brain infusion kit 3,
Durect). Cannulae were stereotaxically implanted at coordinates:
0mm anteroposterior (AP) and 0.9mmmediolateral (ML) to the
bregma. Growth factors were diluted in a vehicle solution (0.1%
BSA in PBS) and infused at 400 ng/day. Animals were sacrificed
after 5 days.
Adult brain electroporations were performed essentially as
described previously (Barnabé-Heider et al., 2008). Briefly,
plasmids were stereotaxically injected into the left lateral ventricle
using a 1ml Hamilton syringe (coordinates: 0mm AP, 0.9mm
ML, 1.5mm dorsoventral, relative to Bregma). Each animal
received an ICV injection of 2µl, delivered over 1.5–2min,
containing 10µg of each plasmid (20µg total). Electrical pulses
(5 pulses, 50ms intervals, 200mv) were delivered using a square
wave electroporator (ECM 830, Harvard Apparatus) with 7mm
Platinum Tweezertrodes (Harvard Apparatus). Animals were
sacrificed after 3 days, which we determined to yield the peak
number of plasmid-expressing cells.
Plasmids were amplified using Maxiprep (Promega), then the
DNA precipitated and resuspended in 10mM Tris-EDTA, pH
8, prior to use. GFAP::myrTomato and pGFAP::myrGFP were
gifts from Robert Benezra (Addgene plasmids # 22671 and 22672
respectively) (Nam and Benezra, 2009). CS2 Flag-Smad6 was a
gift from Joan Massague (Addgene plasmid # 14961) (Hata et al.,
1998). Plasmids were precipitated with ethanol and resuspended
in PBS prior to electroporation.
Tissue Processing
Anesthetized mice were perfused intracardially with 30ml PBS
pH 7.4 (Wisent) followed by 40ml of 4% formaldehyde freshly
prepared from paraformaldehyde (Acros). Brains were removed
and post-fixed overnight at 4◦C. Tissues were cut into 40µm
sections using a vibratingmicrotome (Leica VT1000S) and stored
at−20◦C in antifreeze solution (Bouab et al., 2011).
Immunostaining and TUNEL
Immunostaining experiments were performed either using a 3,3′-
Diaminobenzidine (DAB) detection step (brain sections) or a
fluorescent secondary antibody detection step (brain sections
and cell cultures), as described previously (Bouab et al., 2011;
Grégoire et al., 2014). Antibodies are listed in Table 1.
For Ki67-TUNEL double-labeling on cell cultures,
immunostaining was first performed for Ki67 (1:100, mouse
anti-human Ki67, BD Biosciences), and following the secondary
antibody step, the TUNEL cell death assay (Roche) was used
according to the manufacturer’s instructions. Negative and
positive controls were omission of dUTP and addition of
DNAse (Sigma), respectively. Quantification of Ki67-TUNEL
double-labeling was performed by counting the number of
Hoechst-labeled nuclei that were double-labeled with either Ki67
or TUNEL from 20x photos (8 fields of view by condition).
Quantification of Ki67, Olig2, pS6, and DCX
immunofluorescence staining was performed on brain sections
following ICV infusions. Marker-positive cells were counted at
600x total magnification from 2 sections situated within 1mm
rostral to the level of infusion. Quantifications were performed
contralateral to the side of pump implantation to avoid local
injury responses, were restricted to the lateral (striatal) SVZ, and
were normalized to the length of SVZ quantified (4 animals per
group).
Quantification of GFAP::myrTomato or GFAP::myrGFP-
expressing cells that co-expressed pS6 was performed following
in vivo adult brain electroporations. Five to ten sections within
the electroporated region of the SVZ were processed for
pS6 immunostaining. GFAP::myrTomato or GFAP::myrGFP -
expressing cells were then identified at 600x total magnification
and assessed for co-expression of pS6. A total of 500–1400
reporter-expressing cells were assessed from a total of 7–8
animals per plasmid combination.
Western Blotting
Cultures analyzed by Western blotting were lysed in Ripa Buffer
as previously described (Bouab et al., 2011). Protein samples
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TABLE 1 | Antibody list.
Antibody Compagny Western blot Immunostaining
Actin (mouse) Abcam 1/20000
Alexa-555 goat anti-mouse Invitrogen 1/1000
Alexa-555 goat anti-guinea pig Invitrogen 1/1000
Alexa-488 goat anti-chicken Invitrogen 1/1000
Alexa-488 goat anti-rabbit Invitrogen 1/1000
Alexa-647 goat anti-rabbit Invitrogen 1/1000
CNPase (mouse) Chemicon 1/500
Doublecortin (guinea pig) Chemicon 1/3000
Phospho-4EBP (Thr37/46) (rabbit) Cell signaling 1/1000
Phospho-p44/42 MAPK (ERK1/2) (thr202/tyr204) (rabbit) Cell signaling 1/1000
GFAP (chicken) Novus biological 1/1000
GFAP (rabbit) Dako diagnostic 1/1000
HRP secondary Ab (anti-mouse) Bio-rad 1/5000
HRP secondary Ab (anti-rabbit) Jackson immuno research 1/5000
Ki67 (mouse) BD biosciences 1/100
Olig2 (rabbit) Chemicon 1/1000 1/250
Phospho-mTOR (Ser2448) (rabbit) Cell signaling 1/1000
Phospho-S6 (Ser240/244) (rabbit) Cell signaling 1/1000 1/300
Sox2 (rabbit) Chemicon 1/500
Phospho-Smad1 (Ser463/465)/ Cell signaling 1/1000
Smad5 (Ser463/465)/Smad8(Ser426/428) (rabbit)
ßIII-tubulin (TUJ1) (mouse) Covance 1/1000
for Western Blotting were prepared as described previously
(Bouab et al., 2011; Paliouras et al., 2012), and primary antibody
information is provided in Table 1. HRP-conjugated secondary
antibodies were used at the following dilutions: anti-mouse IgG
(1:5000, Bio Rad) or anti-rabbit IgG (1:5000, Jackson Immuno
Research). Signals were revealed using the Clarity kit (Bio-Rad),
detected using ChemiDoc (Bio-Rad), and quantified using Image
Lab 4.1 software (Bio-Rad).
Flow Cytometry Assays
CarboxyFluorescein Diacetate Succinimidyl Ester
(CFSE) Cell Division Assay
To assess cell division, dissociated neurospheres were treated
with 1µMCSFE (Life technology) at 1 million cells/ml for 8min
at 37◦C. The reaction was quenched with 100% FBS (1–2min),
and the labeled cells were then washed with PBS and DMEM/F-
12 (3:1) medium and subsequently plated onto Poly-L-Lysine
coated dishes at a density of 12,500 cells/cm2 in DMEM/F-12
(3:1) medium supplemented with 2% B27, 1% FBS, and 5 ng/ml
EGF. Cells were treated on day 0 with 100 ng/ml of factors. After
3 days, the cells were harvested by trypsinization, washed and
analyzed on an LSRII cytometer (BD Biosciences). Data analysis
was performed using FlowJo v7.6.5 (Tree Star).
Propidium Iodide and Cell Cycle Analysis
Dissociated neurosphere cells were plated at 25,000 cells/cm2
in medium containing the indicated treatments. Cells were
harvested by trypsinization after 24 h of treatment, rinsed and
frozen in 70% ethanol in PBS until analysis. Prior to flow
cytometry analysis, samples were treated with 0.5mg/ml of
DNAse-free RNAse (Sigma) (30min at room temperature) and
incubated with 50mg/ml of propidium iodide (Sigma).
Statistical Analyses
Statistical comparisons were made using a One-Way analysis of
variance (ANOVA) followed by either Dunnett’s (comparison to
a single control group) or Tukey’s (multiple group comparison)
post-hoc tests. For in vitro experiments, a repeated measures
ANOVA was used as each animal had its own internal Vehicle
control. All statistical analyses were performed using GraphPad
Prism, Version 5.02 (GraphPad Software, Inc).
RESULTS
EGF and BMP Exert Opposing Effects on
SVZ-derived Neural Precursor Proliferation
In order to understand how SVZ neural precursors integrate
conflicting signals, we first sought to identify two factors that
exert opposing effects. To do so, we used the neurosphere
culture system to perform pro- and anti-proliferative assays, and
compared the effects of six distinct families of secreted niche
factors.
To identify proliferation-promoting SVZ signals,
neurospheres expanded from the adult SVZ were dissociated
and plated in a basal survival-promoting medium that was
supplemented with 20 ng/ml of either EGF, FGF, BMP, PDGF,
VEGF, or SHH (Figure 1A). Three days later, cells were lysed
and analyzed biochemically for changes in proliferation and
differentiation markers (Figure 1B). Western blot analysis
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FIGURE 1 | Comparison of the pro- and anti- proliferative effects of 6 families of neurogenesis regulators on SVZ-derived neural precursor cultures.
(A,B) Assay for pro-proliferative effects. Experimental paradigm (see Materials and Methods for details) (A). Western blotting analysis of cell lysates following growth
factor treatments (representative example from 1 of 3 experiments) (B). Note that EGF is the prominent stimulator of markers of proliferation (PCNA) and TAPs (Sox2,
Olig2). (C–E) Assay for anti-proliferative effects. Experimental paradigm (see Materials and Methods for details) (C). Quantification of the effects of growth factor
treatments on neurosphere numbers (D) and sizes (E). Note that BMP exerts a powerful anti-proliferative effect on neural precursors during neurosphere formation.
***p < 0.001, One-Way ANOVA (Dunnett’s post-hoc test). Data are represented as mean ± SEM.
showed that in comparison to the unsupplemented control,
EGF and to a lesser extent FGF were the only factors that
stimulated expression of proliferating cell nuclear antigen
(PCNA) (Figure 1B). Consistent with this, EGF and FGF
increased levels of Sox2 and Olig2, while decreasing levels of
the astrocyte marker GFAP (the principal differentiated cell
type in neurosphere-derived cultures) (Figure 1B). In this
regard, Sox2 is expressed by both NSCs and TAPs in the SVZ.
Although Olig2 normally identifies only a small subset of the
SVZ TAP population, previous studies have shown that the
vast majority of TAPs generated using exogenous EGF/FGF are
Olig2+Sox2+ positive progenitors (Gabay et al., 2003; Lindberg
et al., 2012). Thus, among these six factors, EGF is the prominent
pro-proliferative factor for TAPs.
To identify anti-proliferative SVZ signals, neurospheres were
grown from the dissociated SVZ using a low basal concentration
of 5 ng/ml EGF (EGFlow) to allow neurosphere formation and
further supplemented with 100 ng/ml of each individual factor
(Figure 1C). Quantifications showed that, at the clonal cell
density used to grow neurospheres, treatment with 100 ng/ml
EGF did not further increase the number (Figure 1D) or
size (Figure 1E) of neurosphere colonies compared to the
EGFlow control condition. Likewise, none of the other factors
significantly increased neurosphere number over the EGFlow
condition (Figure 1D), although FGF increased the mean colony
size from 192.4± 3.3 to 227.2± 4.0µm. Notably, however, BMP
treatment reduced the number of neurospheres generated from
the SVZ by more than 50%, and reduced the mean colony size to
139.1± 2.8µm (Figures 1D,E).
Together, these assays identified EGF and BMP as particularly
potent pro- and anti-proliferative factors for SVZ-derived neural
precursors, respectively.
TAPs: BMP Suppresses EGF-induced
Proliferation Via Highly Dominant Effects
on Proliferation, Differentiation, Cell Cycle
Parameters, and Cell Death
TAPs constitute more than 95% of cells within individual
neurospheres and express receptors for both EGF and BMP
(Lim et al., 2000; Doetsch et al., 2002; Peretto et al., 2004;
Pastrana et al., 2009; Codega et al., 2014). To examine how TAPs
respond when simultaneously challenged with EGF and BMP,
we used SVZ-derived neurospheres to generate high density
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adherent cultures for dose-response experiments. Adherent
cultures were treated with either (1) increasing concentrations
of EGF, (2) increasing concentrations of BMP, (3) intermediate
levels of EGF plus increasing concentrations of BMP, or (4)
intermediate levels of BMP plus increasing concentrations of
EGF (Figures 2A,B).
Biochemical analysis showed that cells treated with increasing
concentrations of EGF (5–40 ng/ml) exhibited a dose-dependent
increase in markers of proliferation (PCNA) and TAPs (Sox2,
Olig2) and suppression of astrocytic differentiation (GFAP).
However, neurosphere-derived cells were rendered insensitive to
these proliferation- and TAP-inducing effects of EGF when they
were simultaneously exposed to 20 ng/ml BMP (Figures 2B–H).
Conversely, BMP alone dose-dependently increased markers
of differentiation and had no effect on proliferation and
TAP markers; when simultaneously exposed to a constant
20 ng/ml EGF concentration, increasing the concentration of
BMP suppressed EGF-induced TAP proliferation and increased
differentiation in a dose-dependent manner (Figures 2B–H).
Thus, these dose-response experiments showed that EGF and
BMP have opposing effects on proliferation and differentiation of
TAPs, and that the anti-proliferative/pro-differentiation effects of
BMPs are highly dominant: when combined, BMP but not EGF
is able to exert a dose-dependent suppression of the conflicting
signal.
We next used immunocytochemistry and flow cytometry
assays to better understand the cellular mechanisms involved
in BMP’s dominance over EGF (Figures 2I–Q). Secondary
neurospheres were dissociated and plated for 48 h in a basal
proliferation medium containing 5 ng/ml EGF (EGFlow) that
was further supplemented with either Vehicle, 100 ng/ml
EGF (EGFhi), 100 ng/ml BMP (BMPhi), or both factors
(EGFhi+BMPhi) (Figure 2I). EGFhi–treated cultures did not
contain more cells than the Vehicle group, indicating that the
basal EGFlow concentration maintained maximal proliferation
over this time period. However, BMPhi and EGFhi+BMPhi
groups both contained 55% fewer cells than the Vehicle- and
EGFhi groups (Figures 2J–L). Immunocytochemistry showed
that BMP’s effects are primarily anti-proliferative rather than
pro-apoptotic. The proportion of cells that were in proliferation
(Ki67+) decreased from 53.84 ± 2.80 and 55.19 ± 3.46%
in the Vehicle and EGFhi–treated cultures to 9.34 ± 1.41
and 4.66 ± 1.11% in the BMPhi and EGFhi+BMPhi groups
(Figures 2J–M). Similarly, Olig2 expression decreased from
75.19 ± 6.30 and 70.35 ± 3.34% in the Vehicle and EGFhi–
treated cultures to 26.93 ± 5.50% and 30.86 ± 3.58% in the
BMPhi and EGFhi+BMPhi groups (Figures 2K–N). There was
also a smaller 7.5% increase in the proportion of cells that were
apoptotic (TUNEL+) (Figure 2O). Consistent with BMP’s anti-
proliferative effects, propidium iodide (PI)-based flow cytometry
analyses showed that the BMPhi and EGFhi+BMPhi conditions
both shifted approximately 10% of neural precursors from the S-
and G2-M phases of the cell cycle into G0-G1 within one day of
treatment (Figures 2P,Q).
Notably, the effects of BMPhi and EGFhi+BMPhi conditions
were virtually identical in all of these assays, revealing that
the effects of BMP on neural precursor proliferation, cell cycle
parameters, and apoptosis are all highly dominant to those
of EGF.
Distinct Mechanisms of Proliferation
Inhibition Following EGF withdrawal and
BMP treatment
In order to explore the kinetics of BMP’s suppression of EGF-
induced proliferation, we performed a label retention-based assay
using CarboxyFluorescein Succinimidyl Ester (CFSE). CFSE is
a fluorescent dye that is passively incorporated into cells and
then serially diluted from their cytoplasm during each subsequent
cell division. Dissociated neurosphere cells were pre-labeled with
CFSE, treated under various conditions for 3 days, and then
analyzed for CFSE retention by flow cytometry (Figure 3A). As
expected, control cultures plated under differentiation conditions
of complete EGF withdrawal (No EGF) exhibited 2-fold more
CFSE-fluorescence than the EGFlow-containing Vehicle and
EGFhi conditions. Notably, BMPhi and EGFhi+BMPhi-treated
cultures closely resembled the No EGF differentiation condition,
revealing that suppression of proliferation in response to BMP
treatment follows similar kinetics as following EGF withdrawal
(Figures 3B,C).
mTORC1 signaling is a key mediator of EGF-induced
proliferative expansion of TAPs (Paliouras et al., 2012). Given
the similar suppression of TAP proliferation between EGF
withdrawal and BMP treatment conditions, we asked whether
BMP operates by inhibiting mTORC1 signaling. Neurosphere-
derived cells were exposed to either BMP or the mTORC1
inhibitor Rapamycin for 24 h, then switched to a proliferation
medium containing 20 ng/ml EGF for up to 5 days to
assess recovery of TAP proliferation and mTOR signaling
(Figure 3D). Following treatment with the respective vehicle
solutions (BSA for BMP or DMSO for Rapamycin), cells
switched to the 20 ng/ml EGF proliferation medium exhibited
a continual increase in expression of the proliferation marker
PCNA accompanied by increasing expression of the TAP-
associated mTORC1 pathway markers, pmTOR, pS6, and p4EBP
(Figure 3E). In comparison, cells treated with either BMP or
the reversible mTORC1 inhibitor Rapamycin displayed a rapid
drop in PCNA levels (Figure 3E). In the case of Rapamycin,
this drop was accompanied by immediate disappearance of
the mTORC1 pathway markers, and PCNA and the p4EBP
branch of the mTORC1 pathway subsequently recovered by
day 4 (Figure 3E). In the case of BMP, the decrease in
PCNA levels showed only a delayed and partial recovery,
and notably, levels of pmTOR, pS6, and p4EBP did not
parallel the reduction in PCNA, only displaying a slow and
relatively minor decline over the 5-day period (Figure 3E).
BMP-treated cells showed a strong and transient increase in
pSMAD1/5/8, confirming BMP pathway activation (Figure 3E).
Levels of pERK1/2 (a second proliferation-associated EGFR-
induced pathway) were likewise relatively unchanged by BMP
treatment (Figure 3E).
Further analysis confirmed that the recovery of proliferation
following Rapamycin treatment was associated with a recovery
of the TAP markers Sox2 and Olig2 (Figures 3F–J). In contrast,
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FIGURE 2 | BMP exerts dominant effects over TAP proliferation, differentiation, cell cycle parameters and cell death. (A–H) EGF and BMP dose-response
experiments. Experimental paradigm (see Materials and Methods for details) (A). Western blot analysis of cell lysates following dose-response treatments
(Continued)
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FIGURE 2 | Continued
(representative example from 1 of 2 experiments) (B). Note that EGF-induced effects are suppressed in a dose-dependent manner by BMP, while BMP-induced
effects are insensitive to EGF concentration. Densitometric quantification of markers of proliferation (PCNA) (C), TAPs (Sox2, Olig2) (D,E) and neural subtypes
(astrocytes, GFAP; neurons, ßIII-tubulin; oligodendrocytes, CNPase) (F–H). (I–Q) Effect of EGF and BMP on cell proliferation, death and cell cycle. Experimental
paradigms (see Materials and Methods for details) (I). Immunofluorescence analysis for Ki67 (J) or Olig2 (K), counterstained with Hoechst. Arrowheads and arrows
show examples of positive and negative cells, respectively. Quantification of immunocytochemistry experiments showing the treatment effects on total number of
Hoechst-positive nuclei (L) and proportion of cells that are positive for Ki67 (M), Olig2 (N), or TUNEL (O). Cell cycle analysis by flow cytometry for DNA content using
propidium iodide (representative example from 1 of 3 experiments) (P), with quantification by cell cycle phase (Q). Note that BMP has dominant effects on cell
proliferation, cell cycle and cell death. Scale bar in (J) is 50 microns (for J,K). *p < 0.05, **p < 0.01, ***p < 0.001, One-Way ANOVA (Tukey post-hoc test). Data are
represented as mean ± SEM.
recovery of TAP markers following BMP treatment was limited,
and instead, there was a strong increase in markers of
differentiated astrocytes and neurons. The BMP differentiation
response was primarily astrocytic, as immunocytochemistry
showed the increase in βIII-tubulin was mainly due to enhanced
neuronal morphological complexity (not shown).
This analysis reveals that despite the similarity in their time-
course of proliferation inhibition, EGF withdrawal and BMP
treatment are mechanistically distinct. EGF withdrawal, but
not BMP treatment, is mediated by suppression of mTORC1
signaling. Moreover, TAPs transiently treated with Rapamycin
undergo a reversible inhibition of proliferation, while TAPs
transiently treated with BMP terminally differentiate into
astrocytes despite the ongoing presence of EGF.
NSCs: BMP Promotes NSC Quiescence by
Dominantly Suppressing EGF-induced NSC
Activation
We next focused on the integration of EGF and BMP signals
at the level of activated NSCs, which likewise express receptors
for both EGF and BMP (Doetsch et al., 2002; Colak et al.,
2008; Pastrana et al., 2009; Codega et al., 2014). To do
so, we investigated the individual and combined impacts of
these factors on growth and self-renewal of clonally derived
neurospheres.
To determine whether EGF or BMP is dominant for
activated NSCs, primary neurosphere colonies were grown
at clonal density in the presence of 5 ng/ml EGF to sustain
neurosphere formation (EGFlow) and supplemented with
either BSA (Vehicle), 100 ng/ml EGF (EGFhi), 100 ng/ml BMP
(BMPhi), or 100 ng/ml EGF+100 ng/ml BMP (EGFhi+BMPhi)
(Figure 4A). Quantification showed that there was no difference
in the number (Figure 4B) or size distribution (Figure 4C) of
neurosphere colonies between the Vehicle and EGFhi conditions,
confirming that the EGFlow concentration is saturating at the
clonal cell density required in the neurosphere assay. Consistent
with the anti-proliferative effect of BMP on TAPs described
earlier, BMPhi and EGFhi+BMPhi conditions both significantly
decreased neurosphere number and size (Figures 4B,C).
Importantly, however, further analysis of the size distribution
data showed that BMP reduced the number of full-sized
colonies (larger than 70µm) without increasing the number of
small-sized colonies (less than 70µm) (Figure 4B), indicating
that BMP is also a negative regulator of neurosphere initiation
(NSC activation). Biochemical analysis of these neurospheres
showed that, as expected, EGFlow neurospheres that were
Untreated, Vehicle- or EGFhi–treated all displayed high levels
of the proliferation (PCNA) and TAP (Sox2, Olig2) markers
and virtually undetectable levels of differentiation markers
(βIII-tubulin, GFAP, and CNPase) (Figures 4D–G). However,
this profile was reversed in the neurospheres obtained in the
BMPhi and EGFhi+BMPhi conditions: BMP suppressed the
expression of PCNA, Sox2, and Olig2, and induced expression of
differentiated neuronal and glial markers (Figures 4D–G). Thus,
in the colony-forming neurosphere assay, BMP overcomes the
mitogenic effects of EGF at the level of both TAPs and NSCs.
To determine whether the BMP-induced decrease in
neurosphere initiation was due to NSC loss (terminal
differentiation, death, and/or irreversible senescence) vs.
NSC quiescence (reversible slowing or exit from the cell
cycle), we performed a neurosphere self-renewal assay.
Specifically, we tested whether neurosphere-initiating NSCs
are still present in neurospheres grown in the presence of
BMP. Neurosphere colonies were grown in the same growth
factor combinations as above, but following the generation of
primary neurospheres, 60 neurospheres from each condition
were dissociated and replated at clonal density in standard
neurosphere-forming conditions (Figure 4A, “self-renewal
assay”). Primary neurospheres grown in the BMPhi and
EGFhi+BMPhi conditions again generated smaller primary
neurospheres, and thus contained 65–70% fewer cells (data
not shown) as compared to neurospheres grown in the
Vehicle or EGFhi conditions. However, when these smaller
BMP-treated primary neurospheres were dissociated and
replated under standard neurosphere-forming conditions,
they were found to retain a disproportionately high number
of neurosphere-initiating cells, exhibiting only a 30–35%
decrease (not statistically significant) in secondary neurospheres
generated (Figure 4H). Interestingly, further analysis of these
secondary neurospheres showed that NSCs within the smaller
BMP-treated primary neurospheres actually generated larger
secondary neurospheres (Figure 4I). These larger secondary
neurospheres exhibited a variety of biochemical differences,
including enhanced expression of proliferation (PCNA), TAP
(Sox2, Olig2) and differentiated (βIII-tubulin, GFAP, and
CNPase) neural markers (Figures 4J–M).
These in vitro data reveal that (i) BMP is dominant over
EGF at the level of activated NSCs, (ii) that BMP restrains NSC
expansion by promoting a reversible quiescence rather than NSC
loss, and (iii) that BMP-restrained NSCs subsequently exhibit an
enhanced capacity for proliferation and differentiation.
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FIGURE 3 | Similarities and differences between BMP treatment and EGF withdrawal-induced suppression of TAP proliferation. (A–C) Effect of EGF and
BMP on proliferation kinetics. Experimental paradigm for CFSE experiment (see Materials and Methods for details) (A). CFSE fluorescence intensity curves
(representative example from 1 of 3 experiments) (B), with mean fluorescence (C). Note that BMP completely suppresses EGF-induced dilution of CFSE, a measure of
the number of cell divisions, and is identical to EGF withdrawal. (D–J) Proliferation recovery assay following transient treatment with BMP or Rapamycin. Experimental
paradigm (see Materials and Methods for details) (D). Western blot analysis for proliferation (PCNA), mTORC1 pathway activation (pmTOR, pS6, p4EBP), SMAD
pathway activation (pSMAD1/5/8), ERK pathway activation (pERK1/2), and actin loading control (E). Representative example from 1 of 3 experiments. (F–J) Western
blot analysis for PCNA, TAP (Sox2, Olig2), and differentiation (GFAP, ßIII-tubulin, CNPase) markers (representative example from 1 of 3 experiments) (F). Densitometry
quantifications (G–J). Note BMP and Rapamycin both suppress proliferation, but BMP additionally stimulates differentiation and does not require a decrease in mTOR
pathway activation. *p < 0.05, **p < 0.01, ***p < 0.001, One-Way ANOVA (Tukey post-hoc test in (C), Dunnett’s post-hoc test in (G–J). Data are represented as
mean ± SEM.
BMP Limits EGF-induced Proliferative
Expansion of TAPs In vivo
We next assessed whether the dominant anti-proliferative
effects of BMP are also observed in an in vivo setting.
Intracerebroventricular (ICV) infusions were used to deliver
Vehicle solution (BSA), EGF, BMP, or a combination of
EGF+BMP into the lateral ventricles of adult mice (Figure 5A).
Immunohistochemical analysis after 5 days of infusion indicated
that EGF dramatically increased Ki67+ cell proliferation
surrounding the lateral ventricles, that BMP had no detectable
effect on its own, but that BMP seemed to partially limit
the EGF-induced proliferation (Figure 5B). To quantify and
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biochemical characteristics. *p < 0.05, *p < 0.05, ***p < 0.001, One-Way ANOVA (Tukey post-hoc test). Data are represented as mean ± SEM.
extend these observations, we performed immunofluorescence
for Ki67, Olig2, the neuroblast marker doublecortin (DCX),
and the mTORC1 readout pS6 (Figure 5C). Quantifications
confirmed that EGF, but not EGF+BMP, stimulated a statistically
significant increase in Ki67+ proliferating cells relative to
Vehicle (Figure 5D). EGF is reported to increase the number
of Olig2+ TAPs (Lindberg et al., 2012); we found that the EGF
and EGF+BMP groups both exhibited statistically significant
increases in Olig2+ cells relative to Vehicle, but that the
EGF+BMP group was significantly lower than the EGF group
(Figure 5E). Likewise, pS6 immunoreactivity is mainly expressed
in TAPs, and was significantly increased in the EGF but not
EGF+BMP groups relative to Vehicle (Figure 5F). Neuroblast
numbers were decreased to a similar extent in both the EGF
and EGF+BMP groups relative to Vehicle (Figure 5G). Given
the massive proliferative response to EGF, it was not possible
to reliably quantify numbers of GFAP+ astrocytes or ventricle-
contacting GFAP+Ki67+ NSCs in this paradigm. Notably, while
infusion of BMP by itself showed a tendency to decrease Ki67
and DCX levels compared to Vehicle infusion, it did not
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induce statistically significant changes for any of the markers
examined.
Together, these quantifications reveal that in an in vivo
context, TAP proliferation is induced by exogenous EGF when
EGF is administered alone but not when it is co-administered
with BMP.
Inhibition of Endogenous BMP Signaling
Promotes NSC Activation In vivo
Since it was not possible to study growth factor-induced
changes in NSC proliferation in the infusion paradigm, we
turned to an in vivo adult brain electroporation strategy
that would allow selective targeting of NSCs within their
niche (Barnabé-Heider et al., 2008). To determine whether
inhibition of endogenous BMP signaling can lead to NSC
activation, plasmids expressing GFAP promoter-driven GFP
(GFAP::myr-GFP, to label NSCs) were mixed with plasmids
expressing either SMAD6 (a negative regulator of BMP-
induced SMAD signaling) (Hata et al., 1998) or CMV6
(empty vector). Plasmid mixtures were injected into the
lateral ventricles of adult mice and co-electroporated into the
ventricle walls (Figures 6A,B). Immunofluorescence analysis of
the SVZ 3 days post-electroporation revealed that in mice
electroporated with empty vector, 5.98% (81 of 1353 cells) of
GFAP::myr-GFP-expressing NSCs co-labeled with the mTORC1
readout pS6 (i.e., had undergone activation) (Figures 6B,C).
In mice electroporated with SMAD6, this increased by 52.8%,
to 9.14% of GFAP::myr-GFP-expressing NSCs (50 of 547
cells) (Figure 6C). Thus, endogenous BMP-SMAD signaling
constitutively suppresses NSC activation, and acutely inhibiting
endogenous BMP-SMAD signaling is sufficient to allow an
increase in NSC activation.
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FIGURE 6 | Inhibition of BMP-SMAD signaling in NSCs promotes mTORC1 activity in vivo. (A–C) In vivo electroporation of SMAD6 upregulates mTORC1
signaling in quiescent GFAP-positive NSCs. Experimental paradigm of in vivo adult brain electroporation (see Materials and Methods for details) (A). Representative
immunofluorescence images of GFAP::myrGFP-expressing NSCs that were double-labeled with pS6 (B). Counts of GFAP::myrGFP cells that were double-labeled
with pS6 (data pooled from N = 7− 8 per group) (C). (D) Summary figure: EGF-induced proliferative expansion of TAPs is dominantly suppressed by BMP via distinct
stage-specific mechanisms. (Top) The majority of NSCs in the SVZ niche are quiescent. Upon EGF receptor (EGFR) activation, an NSC divides asymmetrically to
generate a TAP, which undergoes several rounds of proliferative expansion before generating differentiated neural progeny (under normal conditions, predominantly
neurons). (Lower left) At the NSC stage, ligand-induced stimulation of EGFR promotes NSC activation to generate a TAP via asymmetric division. BMP-induced
activation of receptor-regulated SMAD (R-SMAD) dominantly inhibits EGFR-mediated NSC activation to promote NSC quiescence. (Lower right) At the TAP stage,
EGFR stimulation promotes proliferative expansion of TAPs. BMP dominantly inhibits EGFR-mediated TAP proliferation and promotes astrocytic differentiation. Thus,
increased BMP signaling in the SVZ leads depletes the TAP population by promoting quiescence of upstream NSCs and differentiation of TAPs. Scale bar (B) = 25
microns.
DISCUSSION
The present study investigates signal integration during
proliferative expansion of TAPs and their upstream activated
NSCs. Strict regulation of this process is essential for maintaining
a pool of TAPs that can participate in the ongoing replacement of
specific neuronal and glial populations and that can dynamically
modulate production of neural cells in response to changing
local needs (as occurs following tissue injury). Here, we provide
new insights into how TAPs and activated NSCs integrate two
major pro- and anti-proliferation pathways, EGF-mTOR and
BMP-SMAD (Figure 6D).
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Proliferative Expansion of TAPs
EGF-induced mTOR signaling is emerging as a central regulator
of adult neurogenesis. In our previous work, we demonstrated
that EGF-induced mTORC1 signaling plays a critical role
during proliferative expansion of the TAP population (Paliouras
et al., 2012). mTORC1 activity was present in the majority of
proliferating cells in neurosphere cultures in vitro, and in the SVZ
was localized primarily to GFAP-negative cells that were positive
for Ki67 and Mash1 (Paliouras et al., 2012). Such a phenotype
identifies TAPs, but more recent studies suggest it may also
include activated NSCs, which downregulate GFAP expression
and upregulate Nestin (Codega et al., 2014).
We found here that, at the level of TAPs, BMP exerts
completely opposing and highly dominant effects compared to
EGF. A side-by-side comparison of multiple families of SVZ
neurogenesis regulators confirmed that EGF is a particularly
prominent pro-proliferative signal and demonstrated that BMP
is a powerful anti-proliferative signal for neural precursors. BMP
powerfully suppressed overall neural precursor proliferation in
neurosphere-based assays, contrasting the effects of EGF, FGF,
PDGF, VEGF, and SHH, other SVZ neurogenesis regulators.
TAPs represent the vast majority of cells in neurospheres
and neurosphere-derived adherent cultures. Dose-response
experiments were performed to study how TAPs respond to
simultaneous exposure to BMP and EGF, and showed that
BMP’s anti-proliferative effects were unchanged by increasing
and excess levels of EGF, while conversely, EGF’s pro-proliferative
effects were suppressed in a dose-dependent manner by BMP.
Notably, BMP-induced reductions inmarkers of cell proliferation
(adherent cultures) and colony size (neurosphere cultures) were
paralleled by powerful suppression of TAP markers such as Sox2,
Olig2, and the mTOR pathway, and concomitant stimulation
of differentiated neural markers (predominantly GFAP). In
vitro analyses further revealed that BMP’s anti-proliferative
activity rapidly arrested EGF-induced cell division, stimulated
differentiation, increased retention of cells in the G0-G1 phase of
the cell cycle, and marginally increased cell death. These effects
of BMP were opposite to those of EGF, and occurred regardless
of coincident treatment with saturating concentrations of EGF,
revealing that, in vitro, BMP is highly dominant to EGF on TAPs.
We hypothesized that BMP’s anti-proliferative effect may
operate via direct suppression of EGF-induced mTORC1
signaling, based on its dominant effects when co-administered
with EGF, together with the identical kinetics of proliferation
inhibition following BMP treatment and EGF withdrawal (CFSE
experiment). However, unlike Rapamycin, which suppresses
EGF-induced proliferation by directly blocking mTORC1
activity, BMP suppressed proliferation without decreasing
mTORC1 activity. Thus, BMP treatment and EGF withdrawal
suppress proliferation via distinct mechanisms. Inhibition of
proliferation and expression of differentiation markers reached
their maximum 1–2 days after the peak of BMP-induced SMAD
signaling; this suggests that BMP initiates a differentiation
process, but that the cells don’t fully differentiate and stop
proliferating until a few days later. Interestingly, proliferation
recovery following transient Rapamycin treatment was paralleled
by recovery of the 4EBP but not the S6 branch of mTORC1
signaling, consistent with a previous report that 4EBP rather
than S6 kinase may be the main mTOR proliferation effector
(Hartman et al., 2013).
We performed ICV growth factor infusions to validate
these findings in vivo, finding both similarities and differences.
When administered simultaneously in vivo, BMP was indeed
found to attenuate EGF-induced expansion of markers of cell
proliferation (Ki67) and TAPs (Olig2, pS6). However, there was
an apparent difference in the effects of BMP on endogenous
vs. EGF-induced proliferation. Specifically, BMP infusion by
itself had no statistically significant effects on endogenous
levels of Ki67 or TAPs, although a tendency for reduced Ki67
was noted. The most likely explanation for this difference is
that endogenous ependymal-derived noggin may be capable of
blocking exogenously administered BMP (Lim et al., 2000).
Activation of NSCs
BMP was also found to have opposing and dominant anti-
proliferative effects over EGF at the level of activated NSCs.
Because NSCs represent only a few percent of cells within
neurosphere-derived cultures or within the SVZ in vivo,
measuring changes in NSC activity requires specific assays that
can distinguish NSCs from their more abundant TAP progeny.
In vitro, we used the neurosphere culture system to perform
quantitative colony-forming assays. BMP treatment strongly
inhibited EGF-induced neurosphere formation, and notably, this
was not accompanied by an increase in under-sized colonies,
suggesting that BMP had a quiescence-promoting effect on
neurosphere-initiating NSCs. Consistent with this, self-renewal
assays of BMP-treated neurospheres showed that they retained
an almost normal complement of neurosphere-initiating cells,
despite being reduced by more than 80% in neurosphere number
and 65% in cells/neurosphere. Moreover, these BMP-treated
NSCs generated significantly larger neurospheres when returned
to a normal EGF-containing proliferation medium. These in
vitro data indicate that BMP treatment does not cause a loss
of NSCs (i.e., as would occur following terminal differentiation,
death, or senescence); rather, BMP stimulates NSCs to enter a
state of reversible quiescence that reduces their immediate TAP
production but endows them with an enhanced capacity for
subsequent proliferative expansion.
To test whether BMP constitutively restrains NSC activation
in vivo, we turned to a recently developed in vivo adult
brain electroporation protocol (Barnabé-Heider et al., 2008).
Using this approach allowed us to identify and target ventricle-
contacting GFAP-expressing NSCs for genetic manipulation.
Previous studies suggest that 13.3% of NSCs express EGFR
(Pastrana et al., 2009), representing NSCs that are either activated
or primed for activation. Three days after electroporating
quiescent GFAP+ NSCs with a control empty vector, we found
that 6.0% expressed the mTORC1 readout pS6. Electroporating
GFAP+NSCs with a plasmid overexpressing SMAD6, a negative
regulator of BMP-induced SMAD signaling, increased the
percentage of electroporated NSCs that acquire mTORC1 activity
to 9.1%, an increase of over 50%. It is not yet established
whether this mTORC1 activity begins at the stage of stem cell
activation (as occurs in muscle stem cells) (Rodgers et al., 2014)
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or upon generation of a TAP, however these data support a
model in which BMP signaling constitutively represses NSC
activation, and relieving this inhibition is sufficient to allow
initiation of proliferative expansion. Interestingly, the question
of whether prolonged suppression of BMP signaling would lead
to exhaustion of the SVZ NSC pool has not yet been answered.
In the dentate gyrus neurogenic niche, where NSCs have distinct
growth and differentiation properties (Seaberg and van der Kooy,
2002), consensus has also not been reached on this question, with
some studies reporting that that loss of BMP signaling leads to
an eventual loss of NSC activity (Mira et al., 2010) and others
reporting no such loss (Bonaguidi et al., 2008; Gobeske et al.,
2009; Guo et al., 2011).
Together, the present data enable us to begin developing a
picture of how pro- and anti-proliferative signals are integrated
during proliferative expansion of the TAP pool (Figure 6D).
Interestingly, a BMP signaling increase during aging may be a
factor contributing to age-related decline in NSC activity (Yousef
et al., 2015), suggesting that excessive quiescence signaling
can perturb NSC functions under physiological conditions
in vivo. Importantly, BMP-SMAD and EGF-mTOR represent
only selected components of what is most likely a complex,
multi-step and multi-factorial integration process. Indeed, while
BMP suppression increased NSC activation, the majority of
NSCs remained quiescent within the 3 day time-frame examined,
suggesting that other players are involved (Ottone et al.,
2014).
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